

MOLECULAR CANCER THERAPEUTICS

# TABLE OF CONTENTS

**HIGHLIGHTS**

**761 Selected Articles from This Issue**

**SMALL MOLECULE THERAPEUTICS**

**763 Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer**

**AC** Jonathan R. Branch, Tammy L. Bush, Vineet Pande, Peter J. Connolly, Zhuming Zhang, Ian Hickson, Janine Ondrus, Steffen Jaensch, James R. Bischoff, Georges Habineza, Geert Van Hecke, Lieven Meerpoel, Kathryn Packman, Christopher J. Parrett, Yolanda T. Chong, Marco M. Gottardis, and Gilles Bignan

**775 The Discovery of a Novel Antimetastatic Bcl3 Inhibitor**  
Jitka Soukupová, Cinzia Bordoni, Daniel J. Turnham, William W. Yang, Gillian Seaton, Aleksandra Gruca, Rhiannon French, Kok Yung Lee, Athina Varnava, Luke Piggott, Richard W.E. Clarkson, Andrew D. Westwell, and Andrea Brancale

**787 The Monoacylglycerol Lipase Inhibitor JZL184 Inhibits Lung Cancer Cell Invasion and Metastasis via the CB<sub>1</sub> Cannabinoid Receptor**  
Jan Lukas Prüser, Robert Ramer, Felix Wittig, Igor Ivanov, Jutta Merkord, and Burkhard Hinz

**803 Targeting EYA3 in Ewing Sarcoma Retards Tumor Growth and Angiogenesis**  
**AC** Yuhua Wang, Ram Naresh Pandey, Kaushik Roychoudhury, David Milewski, Tanya V. Kalin, Sara Szabo, Joseph G. Pressey, and Rashmi S. Hegde

**816 Identification and Characterization of IMD-0354 as a Glutamine Carrier Protein Inhibitor in Melanoma**  
Yongmei Feng, Gaurav Pathria, Susanne Heynen-Genel, Michael Jackson, Brian James, Jun Yin, David A. Scott, and Ze'ev A. Ronai

**833 Taxanes Sensitize Prostate Cancer Cells to TRAIL-Induced Apoptotic Synergy via Endoplasmic Reticulum Stress**

**AC** Korie A. Grayson, Jacob M. Hope, Wenjun Wang, Cynthia A. Reinhart-King, and Michael R. King

**LARGE MOLECULE THERAPEUTICS**

**846 Robust Antitumor Activity and Low Cytokine Production by Novel Humanized Anti-CD19 CAR T Cells**

Alka Dwivedi, Atharva Karulkar, Sarbari Ghosh, Srisathya Srinivasan, Bajarang Vasant Kumbhar, Ankesh Kumar Jaiswal, Atish Kizhakeyil, Sweetie Asija, Afrin Rafiq, Sushant Kumar, Albeena Nisar, Deepali Pandit Patil, Minal Vivek Poojary, Hasmukh Jain, Shripad D. Banavali, Steven L. Highfill, David F. Stroncek, Niral N. Shah, Terry J. Fry, Gaurav Narula, and Rahul Purwar

**859 A Novel Antibody-IL15 Fusion Protein Selectively Localizes to Tumors, Synergizes with TNF-based Immunocytokine, and Inhibits Metastasis**

Riccardo Corbellari, Marco Stringhini, Jaqueline Mock, Tiziano Ongaro, Alessandra Villa, Dario Neri, and Roberto De Luca

**872 Shaping Functional Avidity of CAR T Cells: Affinity, Avidity, and Antigen Density That Regulate Response**

Raanan Greenman, Yoav Pizem, Maya Haus-Cohen, Alona Goor, Guy Horev, Galit Denkberg, Keren Sinik, Yael Elbaz, Vered Bronner, Anat Globerson Levin, Galit Horn, Shai Shen-Orr, and Yoram Reiter  
See related article, p. 946

**885 Dolaflexin: A Novel Antibody-Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect**

**AC** Aleksandr V. Yurkovetskiy, Natalya D. Bodyak, Mao Yin, Joshua D. Thomas, Susan M. Clardy, Patrick R. Conlon, Cheri A. Stevenson, Alex Uttard, LiuLiang Qin, Dmitry R. Gumerov, Elena Ter-Ovanesyan, Charlie Bu, Alex J. Johnson, Venu R. Gurijala, Dennis McGillicuddy, Michael J. DeVit, Laura L. Poling, Marina Protopopova, Ling Xu, Qingxiu Zhang, Peter U. Park, Donald A. Bergstrom, and Timothy B. Lowinger

# TABLE OF CONTENTS

**896 The Dolaflexin-based Antibody-Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b**

**AC** Natalya D. Bodyak, Rebecca Mosher, Aleksandr V. Yurkovetskiy, Mao Yin, Charlie Bu, Patrick R. Conlon, Damon R. Demady, Michael J. DeVit, Dmitry R. Gumerov, Venu R. Gurijala, Winnie Lee, Dennis McGillicuddy, Peter U. Park, Laura L. Poling, Marina Protopova, LiuLiang Qin, Cheri A. Stevenson, Elena Ter-Ovanesyan, Alex Uttard, Dongmei Xiao, Jian Xu, Ling Xu, Donald A. Bergstrom, and Timothy B. Lowinger

**906 Interleukin-4 Receptor Inhibition Targeting Metastasis Independent of Macrophages**

Megan M. Cleary, Narendra Bharathy, Jinu Abraham, Jin-Ah Kim, Erin R. Rudzinski, Joel E. Michalek, and Charles Keller

**915 Antitumor Activity of NLG207 (Formerly CRLX101) in Combination with Enzalutamide in Preclinical Prostate Cancer Models**

Keith T. Schmidt, Cindy H. Chau, Jonathan D. Strobe, Alwin D.R. Huitema, Tristan M. Sissung, Douglas K. Price, and William D. Figg

**925 Preclinical Assessment of AMG 596, a Bispecific T-cell Engager (BiTE) Immunotherapy Targeting the Tumor-specific Antigen EGFRvIII**

Alexander Sternjak, Fei Lee, Oliver Thomas, Mercedesz Balazs, Joachim Wahl, Grit Lorenczewski, Ines Ullrich, Markus Muenz, Benno Rattel, Julie M. Bailis, and Matthias Friedrich

## CANCER BIOLOGY AND TRANSLATIONAL STUDIES

**934 PGE2 Released by Pancreatic Cancer Cells Undergoing ER Stress Transfers the Stress to DCs Impairing Their Immune Function**

Maria Saveria Gilardini Montani, Rossella Benedetti, Silvia Piconese, Fabio Maria Pulcinelli, Anna Maria Timperio, Maria Anele Romeo, Laura Masuelli, Maurizio Mattei, Roberto Bei, Gabriella D'Orazi, and Mara Cirone

## MODELS AND TECHNOLOGIES

**946 Phenotypic Models of CAR T-Cell Activation Elucidate the Pivotal Regulatory Role of CAR Downmodulation**

Raanan Greenman, Yoav Pizem, Maya Haus-Cohen, Guy Horev, Galit Denkberg, Shai Shen-Orr, Jacob Rubinstein, and Yoram Reiter


See related article, p. 872

**AC** AC icon indicates AuthorChoice

For more information please visit [www.aacrjournals.org](http://www.aacrjournals.org)

## ABOUT THE COVER

In this month's cover, Dwivedi and colleagues demonstrate the binding of a single chain variable fragment (scFv) of the humanized anti-CD19 CAR with CD19 target antigen, obtained through molecular modelling. The unique composition of amino acid residues of the framework region as well as the complementary determining regions (CDRs) of the scFv resulted into the scFv interaction to the CD19 antigen with high binding affinity and with high structural flexibility. Further preclinical and ex vivo studies confirmed that the distinct structural modification in CAR design confers the novel humanized anti-CD19 CAR with a favorable balance of efficacy to toxicity. Read the article on page 846.



# Molecular Cancer Therapeutics

**20 (5)**

*Mol Cancer Ther* 2021;20:761-957.

**Updated version** Access the most recent version of this article at:  
<http://mct.aacrjournals.org/content/20/5>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/20/5>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.